N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=235 Type 2 Diabetes Exemplar: A Remote Care Service for North West London
Type 2 Diabetes Mellitus
Primary: % Participants Downloading Huma App — 95; 0 Participants
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Phase 3 N=127 Vitamin D for Established Type 2 Diabetes (DDM2)
Type 2 Diabetes
Primary: Disposition Index — 0.023; 0.149 index
Phase 1 N=33 Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
Type 1 Diabetes Mellitus · Maturity-Onset Diabetes of the Young, Type 2 · MODY2
Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min
N/A N=127 Low-carbohydrate Versus Low-fat Breakfast in Type 2 Diabetes
Dietary Habits
Primary: Change From Baseline Hemoglobin A1c at 12 Weeks — -0.3; -0.1 % of HbA1c
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1
N/A N=55 Type 2 Diabetes and Exercise Function in Single Leg Exercises
Type 2 Diabetes
Primary: Change in Muscle Oxygen Saturation — -10.7127; -8.9149; -12.471; -8.7883 percentage
N/A N=62 Evaluating a Type 2 Diabetes Prevention Program
Type 2 Diabetes · PreDiabetes
Primary: Body Mass Index (BMI) - Post-Test — 30.3; 28.8 kg/m2
Phase 4 N=12 Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Glycemic Variability: Mean Amplitude of Glucose Excursion (MAGE) — 75.2; 68.5 mg/dl — p=0.630
Phase 1 N=20 A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose — 0.92; 0.98 h*nmol/L — p=0.02
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
N/A N=52 Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
Type2 Diabetes
Primary: Program Enrollment Rate (%) — 14 Percentage of participants
N/A N=30 Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
Diabetes Mellitus
Primary: Change in Hyperglycemia (Percent Change in HbA1c) — -2.2; -1.0 HbA1c percent change
N/A N=30 Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in HgbA1c — -1.9 percentage of glycosylated hemoglobin
N/A N=40 Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation
Overweight and Obesity · PreDiabetes · Insulin Resistance
Primary: Feasibility of CGM Use to Determine Type 2 Diabetes Risk — 33; 5 Participants
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
N/A N=64 TRE in Type 2 Diabetes (See Food Study 3)
Type2Diabetes
Primary: Change in Glycemic Measures- HbA1c (12w) — -0.22; -0.25 percentage of glycated hemoglobin
N/A N=18 Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Insulin Sensitivity · Multiple Mitochondrial Dysfunctions Syndrome
Primary: Change in Insulin Sensitivity — 3.18; 3.85; 3.57; 5.22 mg/kg.min per µU/ml
N/A N=358 Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
Type2 Diabetes
Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
N/A N=507 Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
Type 2 Diabetes
Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24
N/A N=60 Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes
Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
N/A N=18 Adaptation of a Digital Weight Loss Intervention Promoting Self-regulation for Use in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Overweight and Obesity
Primary: Change in Weight — -4.54 kg
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=17 Chronic Passive Heating in Individuals With T2DM
Type2 Diabetes
Primary: Insulin Sensitivity — 0.31; 0.33; 0.10; 0.10 AU
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
N/A N=2,423 Vitamin D and Type 2 Diabetes Study
Prediabetes · Type 2 Diabetes
Primary: Time to Development of Diabetes — 323; 293 Participants